Zhejiang Anglikang Pharmaceutical announced that its subsidiary, Zhejiang Anglikang Pharmaceutical Technology Co., Ltd., has received the 'Pharmaceutical Registration Certificate' for Levocarnitine Oral Solution issued by the National Medical Products Administration. This pharmaceutical is used for the treatment of primary systemic carnitine deficiency and also for the short-term and long-term treatment of secondary carnitine deficiency caused by congenital metabolic abnormalities.
昂利康：子公司获左卡尼汀口服溶液药品注册证书
Zhejiang Anglikang Pharmaceutical: Subsidiary obtains registration certificate for oral solution of levocarnitine pharmaceutical.
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
Hot News
Updated